Anthony El-Khoueiry, MD, is the Associate Director for Clinical Research at USC Norris and an Associate Professor of Clinical Medicine at the Keck School of Medicine of USC. Dr. El-Khoueiry completed his medical degree, residency in internal medicine and fellowship in hematology and oncology at USC. He has extensive experience in clinical and translational research through his roles as medical director of the Clinical Investigations Support Office and director of the phase I program at the USC Norris. He is the recipient of the National Cancer Institute Cancer Investigator Team Leadership Award in 2011.

Dr. El-Khoueiry has established an international reputation in the treatment of gastrointestinal cancer and in particularly in research related to hepatobiliary (liver, gall bladder and bile duct) and pancreatic cancers. He is a member of the National Cancer Institute Hepatobiliary Cancers Task Force and chair of the Southwest Oncology Group hepatobiliary cancers subcommittee. He has lead several multicenter trials in HCC such as the phase II study of guadecitabine, a novel hypomethylating agent, and a phase I/II study of the anti-PD-1 antibody Nivolumab (checkmate 040) in patients with advanced hepatocellular carcinoma which was published in Lancet and resulted in accelerated approval by the FDA. He also served on the steering committee of international studies such as the randomized phase 3 study of cabozantinib versus placebo in patients with HCC who failed or are intolerant of sorafenib and which culminated in the approval of cabozantinib for advanced HCC. He is currently the lead investigator on an international phase Ib study combining pembrolizumab and regorefanib in advanced hepatocellular carcinoma. His other research interest includes drug development as manifested through his leadership of several first-in-human trials of various novel anti-cancer therapies, including ones that were developed at USC such as PRI 724, a novel Wnt pathway inhibitor, and sEphB4-HSA, an inhibitor of the EphB4-Ephrin B2 interaction with immunomodulatory properties. Lastly, as a member of the Stand up 2 Cancer Epigenetics Dream Team and the USC PI for this collaborative grant, he dedicates part of his time to the evaluation of epigenetics drugs in various solid tumors.